Incyte (NASDAQ:INCY) Stock Price Target Raised at Barclays

Incyte (NASDAQ:INCY) had its price objective boosted by Barclays from $139.00 to $143.00 in a research note published on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on the stock. Canaccord Genuity Group started coverage on shares of Incyte in a research note on Thursday, August 20th. They issued a “buy” rating and a $152.00 target price on the stock. Piper Sandler raised their price target on shares of Incyte from $110.00 to $130.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. lifted their price target on shares of Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a report on Monday, September 28th. Wells Fargo & Company upped their price objective on Incyte from $116.00 to $128.00 and gave the company an “equal weight” rating in a research note on Thursday, October 1st. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Incyte in a report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $132.90.

Incyte Price Performance

Shares of Incyte stock opened at $120.39 on Friday. The firm has a market cap of $24.40 billion, a PE ratio of 55.09, a P/E/G ratio of 4.83 and a beta of 0.74. Incyte has a 1 year low of $89.25 and a 1 year high of $132.60. The stock has a fifty day moving average price of $120.49 and a 200-day moving average price of $108.14.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.26 EPS. As a group, equities analysts anticipate that Incyte will post 1.97 EPS for the current fiscal year.

Insider Buying and Selling at Incyte

In other news, insider Pablo Cagnoni sold 10,801 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total value of $1,356,173.56. Following the sale, the insider owned 183,200 shares of the company’s stock, valued at $23,002,592. The trade was a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Caldwell Trust Co bought a new position in shares of Incyte during the third quarter valued at about $307,000. Compass Financial Management LLC purchased a new stake in shares of Incyte during the third quarter worth about $2,378,000. Mraz Amerine & Associates Inc. bought a new stake in shares of Incyte in the third quarter worth about $201,000. Rakuten Investment Management Inc. grew its stake in shares of Incyte by 10.9% in the third quarter. Rakuten Investment Management Inc. now owns 30,531 shares of the biopharmaceutical company’s stock worth $3,761,000 after purchasing an additional 3,006 shares during the last quarter. Finally, Provenance Wealth Advisors LLC purchased a new position in Incyte during the 3rd quarter valued at about $33,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
• Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
• Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
• Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.